Tovecimig

DB30220InvestigationalProtein Based Therapies

NOV1501 is a biologic drug. NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to...

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form and Delta-like protein 4
Curator reviewed
Code names: ABL001 · CTX-009 · NOV1501

Resolves to

Compound

UNIIYXM6C5LQ2H

Targets

P15692VEGFAQ9NR61DLL4

What you can answer from here — as of June 20, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tovecimig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account